Is cardiovascular disease preventable by vaccination?

Annals of Medicine

Volumn 31, Issue 1, 1999, Pages 61-65

  Mäkelä, P Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Acute myocardial infarction; Cardiovascular disease; Chlamydia pneumoniae; Vaccine

Indexed keywords

BACTERIAL VACCINE;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION;

EID: 0032972273     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899909019263     Document Type: Short Survey

References (32)

1. Saikku P, Leinonen M, Mattila KJ, Ekman MR, Nieminen MS, Mäkelä PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-6.
2. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121-8.
3. Thom DH, Grayston JT, Siscovic DS, Wang S-P, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
4. Melnick S, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang S-P, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993; 95: 499-504.
5. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman M-R, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-7.
6. Linnanmäki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130-4.
7. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158-61.
8. Gibbs RGJ, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998; 85: 1191-7.
9. Moazed TC, Kuo C, Grayston JT, Campbell LA. Experimental rabbit models of Chlamydia pneumoniae infection. Am J Pathol 1996; 148: 667-76.
10. Moazed TC, Kuo C-C, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Inf Dis 1997; 177: 1322-5.
11. Moazed TC, Kuo C, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175: 883-90.
12. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-6.
13. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-7.
14. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 1995; 21 Suppl 3: S244-52.
15. Grayston JT, Campbell LA, Kuo CC, Mordhurst CH, Saikku P, Thom DH, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-25.
16. Kauppinen MT, Herva E, Kujala P, Leinonen M, Saikku P, Syrjälä H. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330-5.
17. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96: 4095-103.
18. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.
19. Fryer RH, Schwobe EP, Woods ML, Rodgers GMJ. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997; 45: 168-74.
20. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996; 21: 215: 21.
21. Fong IW, Chiu, B, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52.
22. Laitinen K, Laurila A, Pyhäla L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immum 1997; 11: 4832-5.
23. Kaukoranta-Tolvanen S-SE, Laurila AL, Saikku P, Leinonen M, Liesirova L, Laitinen K. Experimental infection of Chlamydia pneumoniae in mice. Microb Pathog 1993; 15: 293.
24. Laitinen K, Laurila AL, Leinonen M, Saikku P. Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect Immun 1996; 64: 1488-90.
25. Sowa S, Sowa J, Collier LH, Blyth WA. Trachoma vaccine field trials in The Gambia. J Hyg (Lond) 1969; 67: 699-717.
26. Magee DM, Igietseme JU, Smith JG, Bleicker CA, Grubbs BG, Schachter J, et al. Chlamydia trachomatis pneumonia in the severe combined immunodefiency (SCID) mouse. Reg Immunol 1993; 5: 305.
27. Yang X, HayGlass KT, Brunham RC. Genetically determined differences in IL-10 and IFN-γ responses correlate with clearance of Chlamydia trachomatis in mouse pneumonitis infection. J Immunol 1996; 156: 4338.
28. Johansson M, Schön K, Ward M, Lycke N. Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-γ: is this true for humans? Scand J Immunol 1997; 46: 546-52.
29. Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-dependent and -independent pathways. J Immunol 1997; 158: 3344-52.
30. Rottenberg ME, Rotfuchs ACG, Gigliotti D, Svanholm C, Bandholtz L, Wigzell HJ. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. Immunology (in press).
31. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48.
32. Fu T-M, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoproteins induced by DNA immunization. J Virol 1997; 71: 2715-21.